Indivior PLC (INDV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company has raised its financial guidance for 2025, indicating strong performance and growth expectations. The Q&A section reveals effective cost management and strategic focus on SUBLOCADE's growth, with positive indicators such as increased dispense growth and prescriber base. Despite some management evasiveness, the overall sentiment is positive, supported by strong financial metrics and optimistic guidance.
Key Financial Performance
Total net revenue $314 million, increased 2% year-over-year. The increase was driven by SUBLOCADE net revenue growth, which offset expected pricing pressure on SUBOXONE Film and the continued wind down of PERSERIS.
SUBLOCADE net revenue $219 million, increased 15% year-over-year. This growth was attributed to an 8% year-over-year dispense volume growth and included a gross to net benefit of $10 million and a stocking benefit of $4 million.
Adjusted EBITDA $120 million, up 14% year-over-year. The increase was driven by higher net revenue and lower operating expenses.
Non-GAAP operating expenses $145 million, down 3% year-over-year. This decrease was due to the reprioritization of pipeline activities and benefits from restructuring R&D and Medical Affairs organizations.
Gross cash and investments $473 million, up from $347 million at year-end. The increase was driven by approximately $200 million of cash flow from operations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SUBLOCADE growth: SUBLOCADE net revenue grew 15% year-over-year in Q3 2025, with an 8% increase in dispense volume. The product remains the #1 prescribed long-acting injectable in its category.
Direct-to-consumer campaign: A new campaign, 'Move Forward in Recovery,' was launched on October 1, 2025, to raise awareness and reduce stigma around opioid use disorder. It uses an omnichannel approach, including TV, digital, and social media.
Market focus shift: The company is optimizing its Rest of World business to focus on Australia, Canada, France, and Germany, which generate 77% of forecasted Rest of World net revenue and 94% of forecasted adjusted EBITDA.
Cost reduction: Actions taken to simplify the organization are expected to result in annual operating expense savings of at least $150 million starting in 2026. The 2026 operating budget will not exceed $450 million.
Organizational restructuring: The company restructured its R&D and medical affairs organizations, discontinued sales and marketing for OPVEE, and consolidated its operating footprint. It also plans to change its domicile from the U.K. to the U.S.
Indivior Action Agenda: The company is completing Phase 1, 'Generate Momentum,' and preparing for Phase 2, 'Accelerate,' starting January 1, 2026. This includes actions to simplify operations and investments to accelerate SUBLOCADE growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Legal Risks: The company has announced its intention to pursue a change in domicile from the U.K. to the U.S., which may involve regulatory and legal complexities. Additionally, the discontinuation of sales and marketing efforts for OPVEE while meeting contractual and regulatory obligations could pose compliance challenges.
Operational Simplification Risks: The restructuring of R&D and medical affairs organizations, along with the consolidation of the operating footprint and discontinuation of certain activities, may lead to potential disruptions or loss of key capabilities.
Market and Competitive Risks: SUBLOCADE's growth is heavily reliant on improved commercial execution and maintaining its position as the #1 prescribed long-acting injectable in its category. Any failure to sustain this momentum or respond to competitive pressures could adversely impact revenue.
Financial Risks: The company is targeting significant cost reductions, including $150 million in annual operating expense savings starting in 2026. However, achieving these savings without negatively impacting operations or growth initiatives could be challenging.
Geographical Focus Risks: The optimization of the Rest of World business to focus on a few key markets (Australia, Canada, France, and Germany) may limit growth opportunities in other regions and increase dependency on these markets.
Economic and Pricing Risks: The company is benefiting from price stability in SUBOXONE Film in the U.S., but any future pricing pressures could impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Financial Guidance: Total net revenue guidance increased to $1.18 billion to $1.22 billion, reflecting better-than-expected year-to-date performance of SUBLOCADE and stability in U.S. SUBOXONE Film pricing. SUBLOCADE's full-year 2025 net revenue guidance raised to $825 million to $845 million, representing year-over-year growth of 10% at the midpoint. Adjusted EBITDA guidance raised to $400 million to $420 million, an increase of 15% versus 2024 at the midpoint.
SUBLOCADE Growth Projections: SUBLOCADE net revenue is expected to grow 10% year-over-year at the midpoint in 2025. Growth is driven by improved commercial execution, including a new direct-to-consumer campaign launched on October 1, 2025. The campaign aims to raise awareness and educate patients about SUBLOCADE as a treatment option for opioid addiction.
Operating Expense Reductions: Annual operating expenses are expected to reduce by at least $150 million starting in 2026, with the 2026 operating budget not exceeding $450 million. These reductions result from organizational simplifications, including restructuring R&D and medical affairs, discontinuing OPVEE sales and marketing, and optimizing the Rest of World business.
Phase 2 of Indivior Action Agenda: Phase 2, Accelerate, begins on January 1, 2026, focusing on accelerating U.S. SUBLOCADE growth and profitability. The company expects to immediately accelerate cash generation and profitability at a faster rate in 2026.
Rest of World Business Optimization: The company is optimizing its Rest of World business to focus on Australia, Canada, France, and Germany, which generate 77% of forecasted Rest of World net revenue and 94% of forecasted adjusted EBITDA. This optimization aims to reduce organizational complexity and improve financial performance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you break down the new $150 million OpEx cuts for 2026? How much of this was from the recent restructuring plans and how much of the OUS optimization is factored into this number?
A:The $150 million OpEx cuts are broken into four categories: nearly half is tied to labor with a 32% headcount reduction, reduction of nonessential spend across business functions, discontinuation of OPVEE sales and marketing, and optimization of the rest of the world.
Q:Where do you see yourself relative to peers on SG&A spend, and is your goal to get to the peer average or better?
A:The company is not focused on targets but on maximizing SUBLOCADE opportunities in the U.S. and ensuring investments are essential to maximizing the portfolio in Canada and Australia. The focus is on creating shareholder value rather than achieving peer averages.
Q:Can you speak about the opportunity in gaining traction in commercial patients and balancing that with the core Medicaid population?
A:The company aims to grow both Medicaid and commercial channels. Efforts include improved commercial execution, messaging, and ensuring broad coverage with 95% of commercial patients having zero out-of-pocket costs. The commercial channel is growing, and efforts are expected to show impact by 2026.
Q:Can you contextualize R&D spend going forward given organizational changes?
A:R&D and medical team costs have been consolidated. The focus is on progressing Phase II assets through 2025 with readouts in 2026. If ready for Phase III, the company has the capability to proceed without increasing OpEx in 2026.
Q:Are we seeing a meaningful increase in willingness to prescribe SUBLOCADE from label updates?
A:The company is seeing improved commercial execution, awareness from label changes, and significant investments in commercial efforts. They are committed to maximizing SUBLOCADE's potential in the U.S. and will provide 2026 guidance in January.
Q:What are your thoughts on capital allocation given the strengthening balance sheet?
A:The company is focused on completing Phase I of the Indivior Action Agenda and internal planning. They aim to have a clear line of sight to the top line and cash generation before making decisions on capital allocation.
Q:Are there any benefits seen in average duration of use for SUBLOCADE patients or conversion of prescriptions into dispensed prescriptions?
A:Positive indicators include 8% year-over-year dispense growth and an increase in prescriber base. Efforts to improve conversion and duration of use are ongoing, with expected impact in 2026.
Q:Does the OpEx guide for 2026 imply that the rest of the world is streamlined by January 1, 2026?
A:Yes, the $450 million OpEx budget includes the go-forward model for both the U.S. and the rest of the world business.
Q:Does the R&D guidance assume Phase II assets progress into Phase III?
A:The company has preserved the capability to advance programs into Phase III if data supports it, without increasing OpEx in 2026.
Q:What do you need to see from the SUBLOCADE business to move into Phase III?
A:The company needs to demonstrate internal capabilities and external credibility. They are focused on executing Phase I and transitioning to Phase II. If they earn their way to Phase III, they will focus on commercial stage assets that enhance growth and diversify revenue.
Q:What is the long-term path to peak sales in SUBLOCADE or peak penetration in the LAI market?
A:The company is focused on improving commercial execution and driving LAI category growth. They aim to educate OUD patients and drive traffic to treaters' offices. While not predicting peak penetration, they reference other markets achieving 20-25% penetration as a potential benchmark.
Q:What are the details on SUBLOCADE's gross-to-net in the quarter?
A:Q3 net revenue for SUBLOCADE was $219 million, up 15% year-over-year. This included a $10 million gross-to-net release and $4 million from shipment phasing, totaling a $14 million benefit in the quarter.
Q:What is the visibility on SUBOXONE pricing and erosion?
A:For 2025, the company assumes price stability and a slow decline in share. They will provide further details on 2026 dynamics in their guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific targets or benchmarks for SG&A spend relative to peers, instead emphasizing a focus on maximizing opportunities and shareholder value. They also deferred detailed comments on SUBLOCADE's 2026 performance and capital allocation decisions until future updates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accelerate Indivior
Action Agenda
Agenda Phase
Film price
II Accelerate
Indivior Action
Indivior action
LAI
Officer Chief
Phase II
Phase Indivior
Ryan
SUBOXONE Film
action Phase
benefit
category
consumer campaign
date
expense
generation
hope possibility
investment
momentum
narrative
organization
people
position action
price stability
progress Phase
recovery progress
remainder
restructuring RD
stability SUBOXONE
INDV Transcript
Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript
Positive4-30
Despite the absence of strategic updates, the financial performance is strong with a 10% revenue increase, improved gross margins, and a 25% rise in operating income. The positive EPS growth and increased cash flow from operations further support a positive sentiment. The market cap indicates a moderate reaction, leading to a predicted stock price increase of 2% to 8% over the next two weeks.
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Positive2-26
Indivior's earnings call highlights strong financial performance, with SUBLOCADE revenue growth and improved cash flow, despite a significant DOJ payment. Optimistic guidance for 2025 and a focus on shareholder returns through share repurchases are positive indicators. While management avoided some specifics, the overall sentiment in the Q&A was positive, with analysts recognizing growth potential in LAI buprenorphine penetration. The company's strategic focus on new therapeutic areas and operational efficiencies further supports a positive outlook. Given the market cap, the stock is likely to see a positive reaction, estimated between 2% to 8%.
Indivior PLC (INDV) Q3 2025 Earnings Call Transcript
Positive10-30
The company has raised its financial guidance for 2025, indicating strong performance and growth expectations. The Q&A section reveals effective cost management and strategic focus on SUBLOCADE's growth, with positive indicators such as increased dispense growth and prescriber base. Despite some management evasiveness, the overall sentiment is positive, supported by strong financial metrics and optimistic guidance.
Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-8
INDV Slides
INDV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
